Administration of 24-h Intravenous Infusions of Trabectedin in Ambulatory Patients with Mesenchymal Tumors via Disposable Elastomeric Pumps: An Effective and Patient-Friendly Palliative Treatment Option

Patrick Schöffski,Linda Cerbone,Pascal Wolter,Ivo De Wever,Ignace Samson,Herlinde Dumez,Paul Clement,Hans Wildiers,Marguerite Stas

Administration of 24-h Intravenous Infusions of Trabectedin in Ambulatory Patients with Mesenchymal Tumors via Disposable Elastomeric Pumps: An Effective and Patient-Friendly Palliative Treatment Option

2012

Patrick Schöffski
Linda Cerbone
Pascal Wolter
Ivo De Wever
Ignace Samson
Herlinde Dumez
Paul Clement
Hans Wildiers
Marguerite Stas

Background: Patients with progressive mesenchymal tumours after standard chemotherapy have poor outcome. Trabectedin is approved in Europe as 24-h intravenous (i.v.) infusion q3w in

Keywords:

Ambulatory
Mesenchymal stem cell
Dexamethasone
Trabectedin
Sarcoma
Progressive disease
Chemotherapy
Surgery
Adverse effect
Anesthesia
Medicine
Catheter
Thrombosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations